- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01466465
Vitamin D and Grass Pollen Specific Immunotherapy
June 24, 2015 updated by: Margitta Worm, Charite University, Berlin, Germany
Allergen-specific immunotherapy is the only causal therapy of Immunoglobulin E-induced allergies like allergic rhinoconjunctivitis.
Despite progress during the last decades it is limited by a long treatment time and high non-responder frequency.
Based on experimental and epidemiological evidences we hypothesize that vitamin D can act as an effective immunomodulatory adjuvant to overcome these limitations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité Universitätsmedizin Berlin, Allergy-Centre-Charité, CCM
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- written informed consent
- relative Vitamin D deficiency
- clinical relevant grass pollen allergy
- positive intradermal test with grass pollen
- forced expiratory volume at one second (FEV1) > 70%
Exclusion Criteria:
- current specific immunotherapy
- instable allergic asthma
- pregnancy and lactation
- treatment with immunomodulators or immunosuppressive drugs
- sarcoidosis, chronic diseases, malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Vigantol
|
given orally, once daily, before grass pollen season
Other Names:
|
PLACEBO_COMPARATOR: neutral oil (vigantol carrier)
|
given orally, once daily, before grass pollen season
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
wheal diameter in the intradermal test after SIT in the comparison between vitamin D and placebo
Time Frame: three years
|
three years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Worm Margitta, MD, Prof., Charite University, Berlin, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (ACTUAL)
January 1, 2015
Study Completion (ACTUAL)
January 1, 2015
Study Registration Dates
First Submitted
November 1, 2011
First Submitted That Met QC Criteria
November 7, 2011
First Posted (ESTIMATE)
November 8, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
June 25, 2015
Last Update Submitted That Met QC Criteria
June 24, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ProGIT
- 2010-021775-80 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinoconjunctivitis
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
Immunomic Therapeutics, Inc.CompletedAllergic RhinoconjunctivitisUnited States
-
ALK-Abelló A/SCompleted
-
Medical University of GrazRecruiting
-
Immunomic Therapeutics, Inc.Completed
-
University of ZurichCompletedAllergic RhinoconjunctivitisSwitzerland
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic RhinoconjunctivitisSwitzerland
-
ClinNovis GmbHCompletedRhinoconjunctivitis, AllergicGermany
Clinical Trials on Cholecalciferol
-
Medical University of South CarolinaTerminatedVitamin D Deficiency | Nutritional DeficiencyUnited States
-
Centre of Postgraduate Medical EducationUnknownInfant, Premature, DiseasesPoland
-
Johns Hopkins UniversityNational Institute on Aging (NIA)TerminatedVitamin D Deficiency | FallsUnited States
-
Rashid Centre for Diabetes and ResearchCompletedObesity | Type 2 Diabetes Mellitus | Hypovitaminosis DUnited Arab Emirates
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverCompletedInflammationUnited States
-
University Hospital, AngersMylan LaboratoriesCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisLaboratoire CrinexCompletedRenal Transplant Candidate for Right KidneyFrance